市場調査レポート
商品コード
1084492
呼吸器感染症治療の世界市場:規模、シェア、動向、予測(2022年~2028年)Respiratory Tract Infection Treatment Market - Size, Share, trends, and Forecast, 2022 - 2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
呼吸器感染症治療の世界市場:規模、シェア、動向、予測(2022年~2028年) |
出版日: 2022年05月25日
発行: Coherent Market Insights
ページ情報: 英文 157 Pages
納期: 2~3営業日
|
世界の呼吸器感染症の市場規模は、肺疾患の増加、高齢者の増加、小児における肺炎リスクの上昇、大気汚染の増加などによって促進されています。
当レポートでは、世界の呼吸器感染症治療市場を調査しており、市場の概要、市場規模や予測、動向、成長要因、抑制要因、医薬品クラス・適応症・流通チャネル・地域別の分析、および競合情勢などを提供しています。
Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx), voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime, usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone respiratory tract infection are easily transmitted and very contagious while bacterial infection can also be developed during the course of an upper respiratory tract infection. Respiratory tract infection is generally divided into two categories- upper respiratory tract infection (infection in nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).
The global respiratory tract infection market is expected to witness lucrative growth due to factors such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children worldwide. The prevalence of such viral diseases is expected to drive growth of the global market over the forecast period.
Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies have shown effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies.
However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration (FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for heart attack and stroke.
This report provides in-depth analysis of the respiratory tract infection treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global respiratory tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global respiratory tract infection treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for respiratory tract infection treatment market, research and consulting firms, new entrants, and financial analysts
Global Respiratory Tract Infection Treatment Market, By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
Global Respiratory Tract Infection Treatment Market, By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
Global Respiratory Tract Infection Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Respiratory Tract Infection Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
Antibiotics
Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
Cough Suppressant
Nasal Decongestant
Others
By Disease Indication:
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Abbott Laboratories*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca, Plc
Abbvie Inc.
Boehringer Ingelheim GmbH
Cipla Pharmaceutical Company
GlaxoSmithKline plc
Pfizer Inc.
Merck & Co.
Novartis AG
F. Hoffman La Roche Ltd
Sanofi
Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.